To learn how Xeltis’ restorative hemodialysis access graft, aXess, may be opening new horizons for patients with kidney failure, tune in the Visionary Endovascular and Vascular Education (VERVE) Symposium in Sidney, up to 4 December.
In his talk on Saturday 4 December (10am AET), Professor Frans L. Moll, University Medical Center, Utrecht (NL) will explain how the Xeltis synthetic device may potentially enable an immediate start of hemodialysis upon diagnosis and avoid infections or early failure associated with existing devices when turning into a living blood vessel.
The current standard of care for hemodialysis access is an arteriovenous (AV) fistula, requiring weeks or months to mature to the right size, with many failing to mature within six months. Alternatively, patients may use synthetic AV graft (AVG), which tend to fail early and need repeated interventions, driving morbidity, costs and low quality of life.
“The Xeltis technology platform may offer potentially transformative applications in hemodialysis. Our trial program is proceeding at full speed, thanks to committed clinicians and financial investors. The preclinical results on device patency are remarkably promising. We will be sharing more about aXess progression on this space very soon,” said Xeltis Chief Medical Officer, Jochen Reinhold.
